MaxCyte has entered into a collaboration with Ori Biotech to improve manufacturing efficiencies and broaden the adoption of autologous cell therapies. The partnership combines Ori Biotech’s automated manufacturing platform with MaxCyte’s flow electroporation technology to accelerate production scalability for advanced therapy developers.
By integrating MaxCyte’s clinically validated technology with Ori’s closed, automated system, the collaboration aims to simplify complex production processes, reduce cost of goods, and improve consistency across cell therapy manufacturing workflows. The combined offering is expected to enable faster transition from process development to commercial manufacturing, a key challenge facing developers of autologous cell therapies.
Jason Foster, Chief Executive Officer of Ori Biotech, said:
This partnership supports our shared mission to deliver scalable and cost-effective manufacturing solutions that can expand patient access to life-changing cell therapies.
Doug Doerfler, President and Chief Executive Officer of MaxCyte, added:
By integrating our electroporation technology into Ori’s platform, we can help therapy developers move from research to commercial production more efficiently, enabling more patients to benefit from innovative treatments.
The collaboration aligns with both companies’ goals of improving the scalability and accessibility of personalised medicines. Ori Biotech’s proprietary manufacturing system is designed to close, automate, and digitise cell therapy production, while MaxCyte’s technology supports a range of cell engineering applications through non-viral delivery of molecules to cells.
Both organisations continue to work closely with partners in the advanced therapy ecosystem to accelerate commercial readiness and reduce the barriers to global adoption of cell and gene therapies.
